Presentations

Presentations

TriGUARD 3™ Cerebral Embolic Protection Device Data Review

Jeffrey W. Moses, M.D.

Building the Evidence for CEP in TAVR: A Critical Review of the Clinical Trial Data

Jeffrey W. Moses, MD

Download icon

ProtectionThe Search for Meaningful Measures of ClincialEfficacy: NeuroARCand Beyond

Alexandra Lansky, MD

Download icon

What You Need to Know About Cerebral Embolic Protection (CEP): The Need for CEP

Dr. Martin B. Leon, MD

Update on Clinical Evidence to Support Cerebral Embolic Protection (CEP) During TAVR

Dr. Jeffrey W. Moses, MD

Meaningful End-Points of CEP Clinical Trials to Support Adoptions – Major Stroke, Minor Stroke, Imaging?

Dr. Rahul Sharma, MD

Diagnostic Considerations and NeuroARC

Dr. Alexandra Lansky, MD

TriGUARD 3™ Cerebral Embolic Protection Device Protection During TAVR

Tamim Nazif, M.D.

Practical Considerations and Design Requirements for Clinically Relevant CEP: The Keystone TriGUARD 3™ Cerebral Embolic Protection Device

Tamim Nazif, M.D.

TriGUARD 3™ Cerebral Embolic Protection Device Case

Michael Mack, M.D.

TCT 2017 Keystone Heart Symposium

TVT 2017 Keystone Heart Presentations

Economic Impact of Cerebral Embolic Protection: Important Considerations as TAVR Moves to Lower-Risk Patients

Dr. Hemal Gada, MD, MBA

A critical review of the neurological effects of invasive cardiac procedures

Pieter Stella, MD, PhD

The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

Samir Kapadia, MD

Brain Emboli: Clinical Consequences and Brain Injury

Dr. Kevin Abrams, MD

Mitigating Stroke Risk in TAVR: Important Considerations as TAVR Moves to Lower-Risk Patients

Dr. Benjamin Z. Galper, MD, MPH

Keystone Heart Reflect Neurology

Dr. Daryl Gress

Keystone Importance of DW MRI

John Forrest, M.D.

NeuroProtection with the TriGuard™ Cerebral Embolic Protection Device

Dr. Alexandra Lansky, MD

The Spectrum of Neurologic Events after TAVR: Insights from NueroARC

Dr. Alexandra Lansky, MD

TriGuard™ Cerebral Embolic Protection Device During TAVR: A Multicenter Real World Experience

Dr. Alexandra Lansky, MD

Cerebrovascular Complications after Valve Intervention: Incidence and New Standardized Definitions on behalf of NeuroARC

Dr. Alexandra Lansky, MD

Stay Updated on the latest news from Keystone Heart.